Bremelanotide

FDA-Approved moleculeCompounded form not FDA-approved

Also known as: PT-141, Vyleesi

Melanocortin receptor agonist

How it works: Activates melanocortin receptors in the central nervous system; FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Known risks: Nausea, flushing, headache, injection-site reactions; transient increases in blood pressure and decreases in heart rate; possible skin darkening.
Contraindications: Uncontrolled hypertension or known cardiovascular disease.
Drug interactions: May slow absorption of orally administered medications such as naltrexone.

Citations

Bremelanotide for Hypoactive Sexual Desire Disorder (RECONNECT studies) (2019) · PMID 30640807

This information is educational only and is not medical advice. A licensed provider makes all clinical decisions. Diadara provides no dosing, reconstitution, or administration guidance.

Bremelanotide is provided here for education only — it is not currently offered through Diadara. See what we do offer →